Abbott agrees to voluntarily withdraw obesity drug Meridia from U.S. Market Abbott Laboratories agrees to withdraw its obesity medication MeridiaAbbott Laboratories has agreed to voluntarily withdraw its weight problems medication Meridia from the U men last longer .S. Market because of clinical trial data indicating an elevated risk of heart attack and stroke, the U.S. Food and Medication Administration announced today. Meridia’s continued availability is not justified when you compare the modest weight loss that people achieve on this drug to their risk of heart attack or stroke, stated John Jenkins, M.D., director of the Office of New Drugs in the FDA’s Middle for Medication Evaluation and Analysis .
XIENCE PRIME is based on the stent design of the MULTI-LINK family members. It utilizes cobalt chromium technology and includes a peak-to-valley mechanical design that imparts longitudinal strength and stability to the stent. Furthermore, XIENCE PRIME features one of the thinnest drug eluting stent struts available while maintaining radial power to support the vessel, and it provides excellent presence under X-ray during stent implantation methods. XIENCE PRIME emerges in lengthy lengths up to 38 mm. Abbott is the worldwide innovator in drug eluting stent technology, and U.S. Approval of XIENCE PRIME will further advance our number-one placement in the global medication eluting stent market, stated Robert B.